Alzheimer's

1440: Everything you need to know about Alzheimer's

What is Alzheimer's, and is it different from dementia? In short, yes—Alzheimer's is a specific brain disease that falls under the umbrella of dementia. However it is the most prevalent form of the condition, accounting for 60 to 80% of reported dementia cases.

Visualize the difference between a healthy brain and one with Alzheimer's

The brain has three main parts—the cerebrum, brain stem, and cerebellum—each combining to control the entirety of the body's operations. Alzheimer's progressively deteriorates the circuitry in these structures, resulting in what we see as the symptoms of the disease.

Poor sleep increases the risk of developing Alzheimer's

Brain imaging studies reveal poor sleep leads to production of amyloid beta proteins—molecules linked to Alzheimer’s—which are cleaned from the brain during high-quality sleep. These findings suggest conditions like sleep apnea and insomnia increase the risk of developing the disease.

A dignified later life made possible through dementia villages

Dementia villages are specially designed residential communities tailored for individuals with dementia. These environments offer residents a safe, familiar, and stimulating atmosphere that resembles normal daily life—promoting greater independence, social interaction, and quality of life while discreetly integrating necessary care and support from trained professionals.

The first identification of Alzheimer's was made in 1906

The first case of Alzheimer's disease dates to the early 20th century when Dr. Alois Alzheimer had 51-year-old Auguste Deter as a patient. Deter struggled with sudden memory issues and aggressive, irrational behavior. After Deter's death, Alzheimer examined her brain and found strange collections of molecular pileups.

An analysis of ancient texts found that dementia was rare in ancient Greece.

Early-onset Alzheimer's can appear as early as age 30

Drugs recently approved to slow the progression of Alzheimer's appear to work best when administered as early as possible. Early stages are marked by a low buildup of tau, a protein experts believe clumps into misfolded, neuron-disrupting tangles once clusters of another protein—amyloid beta—have already started causing damage.

Scientists are reevaluating the causes of Alzheimer's beyond the amyloid hypothesis after numerous experimental drugs designed to target that theory have failed.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010

The complexity of Alzheimer's disease, coupled with decades of underfunded research efforts, has left patients with little in the way of effective treatments. In recent years, scientists have synthesized several drugs that studies show can slow the progression of Alzheimer's—though the disease itself remains incurable.

Recent evidence raises the question of whether conventional wisdom about amyloid plaques and their connection to Alzheimer's is wrong.